Timrepigene Emparvovec Fails to Demonstrate Efficacy in Choroideremia

Detailed data from the phase 3 trial, including safety findings, which were in line with previous studies, will be presented at a future scientific meeting.

Unraveling the Genetics of Glaucoma

Details enhance knowledge of biological pathways that contribute to disease pathogenesis.

Benefits of Sustained Anti-VEGF Delivery in Wet-AMD

The chief medical officer of Eyevensys discussed the company’s work in developing sustained drug delivery systems.